Acuna Patrick, Supnet-Wells Melanie Leigh, Spencer Neil A, de Guzman Jan Kristoper, Russo Massimiliano, Hunt Ann, Stephen Christopher, Go Criscely, Carr Samuel, Ganza Niecy Grace, Lagarde John Benedict, Begalan Shin, Multhaupt-Buell Trisha, Aldykiewicz Gabrielle, Paul Lisa, Ozelius Laurie, Bragg D Cristopher, Perry Bridget, Green Jordan R, Miller Jeffrey W, Sharma Nutan
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
The Collaborative Center for X-linked Dystonia-Parkinsonism, Massachusetts General Hospital, Charlestown, MA 02129, USA.
Brain Commun. 2023 Apr 4;5(3):fcad106. doi: 10.1093/braincomms/fcad106. eCollection 2023.
X-linked dystonia parkinsonism is a neurodegenerative movement disorder that affects men whose mothers originate from the island of Panay, Philippines. Current evidence indicates that the most likely cause is an expansion in the gene that may be amenable to treatment. To prepare for clinical trials of therapeutic candidates for X-linked dystonia parkinsonism, we focused on the identification of quantitative phenotypic measures that are most strongly associated with disease progression. Our main objective is to establish a comprehensive, quantitative assessment of movement dysfunction and bulbar motor impairments that are sensitive and specific to disease progression in persons with X-linked dystonia parkinsonism. These measures will set the stage for future treatment trials. We enrolled patients with X-linked dystonia parkinsonism and performed a comprehensive oromotor, speech and neurological assessment. Measurements included patient-reported questionnaires regarding daily living activities and both neurologist-rated movement scales and objective quantitative measures of bulbar function and nutritional status. Patients were followed for 18 months from the date of enrollment and evaluated every 6 months during that period. We analysed a total of 87 men: 29 were gene-positive and had symptoms at enrollment, seven were gene-positive and had no symptoms at enrollment and 51 were gene-negative. We identified measures that displayed a significant change over the study. We used principal variables analysis to identify a minimal battery of 21 measures that explains 67.3% of the variance over the course of the study. These measures included patient-reported, clinician-rated and objective quantitative outcomes that may serve as endpoints in future clinical trials.
X连锁肌张力障碍帕金森综合征是一种神经退行性运动障碍,影响其母亲来自菲律宾班乃岛的男性。目前的证据表明,最可能的病因是一个基因的扩增,这可能是可以治疗的。为了准备X连锁肌张力障碍帕金森综合征治疗候选药物的临床试验,我们专注于确定与疾病进展最密切相关的定量表型指标。我们的主要目标是建立对X连锁肌张力障碍帕金森综合征患者运动功能障碍和延髓运动障碍的全面、定量评估,这些评估对疾病进展敏感且具有特异性。这些指标将为未来的治疗试验奠定基础。我们招募了X连锁肌张力障碍帕金森综合征患者,并进行了全面的口面部运动、言语和神经学评估。测量包括患者报告的关于日常生活活动的问卷,以及神经科医生评定的运动量表和延髓功能及营养状况的客观定量指标。从入组日期起对患者随访18个月,在此期间每6个月评估一次。我们共分析了87名男性:29名基因阳性且入组时有症状,7名基因阳性但入组时无症状,51名基因阴性。我们确定了在研究过程中显示出显著变化的指标。我们使用主变量分析确定了一组最少21项指标,这些指标解释了研究过程中67.3%的方差。这些指标包括患者报告的、临床医生评定的和客观定量的结果,可作为未来临床试验的终点。